Portal de Periódicos da CAPES

Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients

2012; Lippincott Williams & Wilkins; Volume: 43; Issue: 5 Linguagem: Inglês

10.1161/strokeaha.111.639823

1524-4628

Israel Fernández‐Cadenas, Alberto del Río-Espínola, Caty Carrera, Sophie Domingues‐Montanari, Maite Mendióroz, Pilar Delgado, Anna Rosell, Marc Ribó, Dolors Giralt, Manuel Quintana, Mar Castellanos, Vı́ctor Obach, Sergi Martínez, Mari Mar Freijo, Jordi Jiménez‐Conde, Jaume Roquer, Joan Martí‐Fàbregas, Carlos A. Molina, José Álvarez‐Sabín, Joan Montaner,

Blood Coagulation and Thrombosis Mechanisms

Despite the benefits of tissue-type plasminogen activator treatment, some stroke patients experience adverse hemorrhagic transformations (HT). Plasma protein levels of MMP9 have been associated with HT occurrence. We aimed to analyze the association of the MMP9 gene with HT occurrence.We analyzed the MMP9 gene in blood samples from 885 stroke patients treated with tissue-type plasminogen activator by tag-SNP, imputed SNP, direct sequencing, and RNA expression.We did not observe any significant association between MMP9 genetic variations or MMP9 expression and HT occurrence. Moreover, no association was found between MMP9 expression and MMP9 polymorphisms.Genetic variations in the MMP9 gene are not associated with HT occurrence in tissue-type plasminogen activator-treated patients.